Better Therapeutics (BTTX) Stock Price, News & Analysis

Company Overview

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.03
• Volume: 531 shs
• Average Volume: 16,495 shs
• Market Capitalization: $9,972.40
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTTX Stock Analysis - Frequently Asked Questions

How have BTTX shares performed this year?

Better Therapeutics' stock was trading at $0.0001 at the beginning of the year. Since then, BTTX shares have increased by 100.0% and is now trading at $0.0002.
View the best growth stocks for 2025 here.

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Better Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Better Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Cricut (CRCT), Zomedica (ZOM), Wells Fargo & Company (WFC) and Abbott Laboratories (ABT).

Company Calendar

• Today: 5/14/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BTTX
• CIK: 1832415
• Web: mcacquisition.com
• Phone: 415-887-2311
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 49,862,000
• Free Float: 24,233,000
• Market Cap: $9,972.40
• Optionable: Optionable
• Beta: 1.19